Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidural Morphine and Ropivacaine for Abdominal Cancer Pain
NCT05558397Completed
- Sponsor
- Federal University of Alfenas
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of morphine and ropivacaine in cancer pain (2 arms), sponsored by Federal University of Alfenas. Primary endpoint: Assessment of effectiveness of epidural morphine/ropivacaine treatment at 60 days. Started Apr 2018; status: completed.
02
Drugs
morphineropivacaine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT05558397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558397.